)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Neuren Pharmaceuticals
Neuren Pharmaceuticals (NEU) investor relations material
Neuren Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 2026 DAYBUE net sales reached $140m, up 39% YoY; trofinetide income guidance for 2026 rose to $91–93m.
Germany’s October launch generated a $35m first-commercial-sale milestone; Japan Phase 3 results support a planned 2027 regulatory filing.
Financial highlights
Q3 2026 royalty income was $16.4m, up 51% YoY.
Full-year 2026 royalty guidance increased to $56–58m from $53–56m; total trofinetide income guidance rose to $91–93m.
Outlook and guidance
Acadia raised 2026 global DAYBUE net sales guidance to $505–520m from $480–510m, implying 2026 royalty income of $56–58m.
Japan launch could follow a planned 2027 regulatory filing in 2028, subject to regulatory approval; Acadia is pursuing a distribution partner.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neuren Pharmaceuticals
- Dividend declared as royalty income and DAYBUE sales surge, funding R&D and global growth.NEU
H1 2026 - DAYBUE™ sales and royalties grew in Q2 2024, with strong pipeline and global expansion progress.NEUQ2 2024
- DAYBUE royalties fuel robust growth as NNZ-2591 trials advance and capital management evolves.NEUAGM 2026
- 2025 royalty income rose 15% to A$65 million, with strong DAYBUE sales and pipeline advances.NEUH2 2025
- Share buyback of up to 5% approved, with strong cash flows and key clinical programs advancing.NEUInvestor update
- Profit after tax surged to A$15 million, with strong DAYBUE royalties and pipeline advances.NEUH1 2025
- FDA supports pivotal phase III trial for rare disorder; final endpoints pending data.NEUStudy Result
- NNZ-2591 showed significant safety and efficacy in Angelman syndrome, especially in younger children.NEUStudy Result
- Record AUD 166m income, robust DAYBUE growth, and strong pipeline progress in 2024.NEUH2 2024
Next Neuren Pharmaceuticals earnings date
H2 202626 Feb, 2027
Neuren Pharmaceuticals
Next Neuren Pharmaceuticals earnings date
H2 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing new therapies for neurodevelopmental disorders, including conditions that manifest in early childhood and are characterized by impaired brain cell connections and signaling. The company has a deep expertise in the field, accumulated through extensive clinical development efforts. Neuren Pharmaceuticals has gained recognition for developing the FDA-approved treatment, DAYBUE™ (trofinetide), specifically for Rett syndrome, marking a significant advancement in the treatment of this condition. Furthermore, the company is advancing its research and development pipeline with therapies aimed at addressing a range of neurodevelopmental disorders. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.